Oxford BioMedica (LSE:OXB) Interest Expense : £-11.20 Mil (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Oxford BioMedica's interest expense for the six months ended in Dec. 2023 was £ -7.39 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was £-11.20 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Oxford BioMedica's Operating Income for the six months ended in Dec. 2023 was £ -34.21 Mil. Oxford BioMedica's Interest Expense for the six months ended in Dec. 2023 was £ -7.39 Mil. Oxford BioMedica did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oxford BioMedica Interest Expense Historical Data

The historical data trend for Oxford BioMedica's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Interest Expense Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-5.56

-0.91

-0.89

-8.75

-11.20

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.42	-8.28	-0.48	-3.81	-7.39

Oxford BioMedica Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-11.20 Mil.

Oxford BioMedica (LSE:OXB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oxford BioMedica's Interest Expense for the six months ended in Dec. 2023 was £-7.39 Mil. Its Operating Income for the six months ended in Dec. 2023 was £-34.21 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was £107.80 Mil.

Oxford BioMedica's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Oxford BioMedica did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines